The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients.

OBJECTIVE The Collaborative Initial Glaucoma Treatment Study (CIGTS) is a randomized, controlled clinical trial designed to determine whether patients with newly diagnosed open-angle glaucoma (primary, pigmentary, or pseudoexfoliative) are better treated by initial treatment with medications or by immediate filtration surgery. DESIGN Randomized, controlled clinical trial. PARTICIPANTS A total of 607 patients with open-angle glaucoma were enrolled. INTERVENTION Patients randomized to initial medications (n=307) received a stepped regimen of medications to lower intraocular pressure. Those randomized to initial surgery (n=300) underwent trabeculectomy to lower intraocular pressure. MAIN OUTCOME MEASURES Progression in visual field loss constitutes the study's primary outcome variable. Secondary outcomes include health-related quality of life, visual acuity, and intraocular pressure. RESULTS Randomized assignment resulted in a balanced distribution between treatment groups for most demographic and clinical measures assessed at enrollment. More males than females were enrolled (55% were males), and a substantial percentage (38.1 %) of enrollees were blacks. Most enrollees (90.6%) were diagnosed with primary open-angle glaucoma; the remainder had either pseudoexfoliative (4.8%) or pigmentary (4.6%) forms of open-angle glaucoma. CONCLUSIONS Follow-up of this well-characterized group of patients should provide well-rounded guidance, based on both traditional ophthalmic measures and patients' perspectives on their health-related quality of life, on how best to initially treat open-angle glaucoma.

[1]  I L Bailey,et al.  New Design Principles for Visual Acuity Letter Charts* , 1976, American journal of optometry and physiological optics.

[2]  F. Ferris,et al.  New visual acuity charts for clinical research. , 1982, American journal of ophthalmology.

[3]  W. M. Grant,et al.  Why do some people go blind from glaucoma? , 1982, Ophthalmology.

[4]  A. Sommer,et al.  The nerve fiber layer in the diagnosis of glaucoma. , 1977, Archives of ophthalmology.

[5]  J Caprioli,et al.  Progression of disc and field damage in early glaucoma. , 1993, Archives of ophthalmology.

[6]  M. Bergner,et al.  The Sickness Impact Profile: Development and Final Revision of a Health Status Measure , 1981, Medical care.

[7]  D E Gaasterland,et al.  The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients. , 1994, Controlled clinical trials.

[8]  R. Deyo,et al.  Toward clinical applications of health status measures: sensitivity of scales to clinically important changes. , 1984, Health services research.

[9]  R. Hitchings,et al.  The influence of prior therapy on the success of trabeculectomy. , 1990, Archives of ophthalmology.

[10]  C. O'brien,et al.  Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. , 1994 .

[11]  A. Sommer,et al.  Race and primary open-angle glaucoma. , 1985, American journal of ophthalmology.

[12]  Donald Allan,et al.  The benefit of early trabeculectomy versus conventional management in primary open angle glaucoma relative to severity of disease , 1989, Eye.

[13]  R A Deyo,et al.  Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. , 1991, Controlled clinical trials.

[14]  A. Sommer,et al.  An evaluation of optic disc and nerve fiber layer examinations in monitoring progression of early glaucoma damage. , 1992, Ophthalmology.

[15]  R. Hitchings,et al.  Control of chronic simple glaucoma with primary medical, surgical and laser treatment. , 1986, Transactions of the ophthalmological societies of the United Kingdom.

[16]  A. Sommer,et al.  Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. , 1991, JAMA.

[17]  C. O'brien,et al.  Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. , 1994 .

[18]  P Diggory,et al.  Medical treatment of glaucoma--a reappraisal of the risks. , 1996, The British journal of ophthalmology.

[19]  J. Wilensky,et al.  Racial influences in open-angle glaucoma. , 1978, Annals of ophthalmology.

[20]  J. Ainsworth,et al.  Cost analysis of early trabeculectomy versus conventional management in primary open angle glaucoma , 1991, Eye.

[21]  R. Hitchings Primary surgery for primary open angle glaucoma--justified or not? , 1993, British Journal of Ophthalmology.

[22]  R. Hitchings,et al.  Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. , 1994, Ophthalmology.

[23]  L. Radloff The CES-D Scale , 1977 .

[24]  E O'Donoghue,et al.  Beta blockers and the elderly with glaucoma: are we adding insult to injury? , 1995, The British journal of ophthalmology.

[25]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.

[26]  C. Mackenzie,et al.  Can the Sickness Impact Profile measure change? An example of scale assessment. , 1986, Journal of chronic diseases.

[27]  C. Migdal What is the appropriate treatment for patients with primary open-angle glaucoma: medicine, laser, or primary surgery? , 1995, Ophthalmic surgery.

[28]  R. Hitchings,et al.  Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. , 1989, Ophthalmology.

[29]  W. M. Grant,et al.  Race as a risk factor for progressive glaucomatous damage. , 1985, Annals of ophthalmology.